Trial · NCT05281328
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
NCT05281328, Phase 2, Phase 3, Active not recruiting, Camurus AB
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD. Trials, record NCT05281328. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05281328
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
- NCT number
- NCT05281328
- Status
- Active not recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 71 participants, actual
- Lead sponsor
- Camurus AB
- Conditions
- Polycystic Liver Disease
- Interventions
- CAM2029, Placebo
- First posted
- 2022-03-16
- Last updated
- 2026-06-01
- Other registries' IDs
- eudract:2021-003764-27
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Height-adjusted Total Liver Volume (htTLV) | From screening until treatment week 53 | Magnetic resonance imaging (MRI) was used to measure the total liver volume (TLV) at baseline and at Week 53 and was adjusted to the participant's height. The change from baseline to Week 53 was calculated as the difference between htTLV values at Week 53 and baseline. The difference in treatment effect between the groups was presented as a ratio expressed in percentage. |
| Secondary | PLD Symptom (PLD-S) Score | From screening to Week 53 | Change from baseline to Week 53 in the PLD-S measure score. |
| Secondary | htTLV | From screening until treatment weeks 13, 25, 77, 125 and 173 | Change from baseline in htTLV as determined by MRI volumetry |
| Secondary | PLD-S | From screening to weeks 13, 21, 25, 39, 77, 101, 125, 149 and 173 | Change from baseline in the PLD-S measure score |
| Secondary | Height-adjusted Total Kidney Volume (htTKV) | From screening until treatment weeks 13, 25, 53, 77, 125 and 173 | Change from baseline in htTKV as determined by MRI volumetry |
| Secondary | Total Liver Cyst Volume | From screening to treatment weeks 13, 25, 53, 77, 125 and 173 | Change from baseline in total liver cyst volume determined by MRI volumetry |
| Secondary | Estimated Glomerular Filtration Rate (eGFR) | From treatment week 1 to weeks 13, 25, 53, 65, 77, 101, 125, 149 and 173 | Change from baseline in eGFR, assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation using serum concentrations of creatinine and cystatin C |
| Secondary | PLD Impact (PLD-I) Score | From screening to weeks 13, 21, 25, 39, 53, 77, 101, 125, 149 and 173 | Change from baseline in the PLD-I measure score |
| Secondary | Clinical Global Impression of Severity (CGI-S) Score | From treatment week 1 to weeks 13, 21, 25, 53, 77, 101, 125, 149 and 173 | Change from baseline in the CGI-S score |
| Secondary | Patient Global Impression of Severity (PGI-S) Score | From screening to weeks 13, 21, 25, 39, 53, 77, 101, 125, 149 and 173 | Change from baseline in the PGI-S score |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39356039 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05281328
GET https://conductscience.org/api/trials/v1/NCT05281328/registered